

## EMERGING COMPANY PROFILE

# Ranok: a chaperone-based approach to targeted degradation

BY PAUL BONANOS, ASSOCIATE EDITOR

An investor syndicate is backing Chinese biotech Ranok in a \$40 million series B round that will allow the targeted protein degradation company to test its differentiated, chaperone-based approach in its first clinical trial.

Hangzhou-based Ranok Therapeutics Co. Ltd. is deepening its presence in the U.S. as it is poised to enter the clinic, founder and CEO Weiwen Ying told BioCentury. The biotech is preparing to conduct its first clinical trial in the U.S., and has a beachhead in Boston.

The company hasn't yet revealed the target or any planned indications for its most advanced program, which is built on Ranok's chaperone-mediated protein degradation (CHAMP) platform.

CHAMPs are heterobifunctional small molecules that share some traits in common with, but are differentiated from, the more commonly seen proteolysis targeting chimeras (PROTACs) used by several targeted degradation companies.

Both bind on one side to a target molecule, and steer it toward degradation by the ubiquitin proteasome system. But while PROTACs typically do so by binding directly to an E3 ligase, CHAMPs induce proximity to a HSP90 chaperone complex that includes multiple E3 ligases, CSO Kevin Foley told BioCentury.

Ranok believes the approach confers advantages over using PROTACs. Since HSP90 is highly activated in tumor tissues compared with normal tissues, CHAMPs are designed to have a higher therapeutic index and more on-target effects in tumors with fewer side effects in normal tissues, potentially offering a dosing advantage. Foley said the therapeutics may also be able to overcome resistance mechanisms associated with E3 ligase mutations, because the complex includes more than one E3 ligase.

In a presentation in April at the American Association for Cancer Research (AACR) virtual meeting that described degradation of BRD4 as preclinical proof of concept for the platform, Ranok

### COMPANY PROFILE RANOK THERAPEUTICS CO. LTD.

Hangzhou, China

**Technology:** Chaperone-mediated targeted protein degradation

**Origin of technology:** Internally developed  
**Disease focus:** Cancer

**Clinical status:** Preclinical

**Founded:** 2018 by Weiwen Ying, Kevin Foley and Junlin Wang

**Academic collaborators:** Undisclosed  
**Corporate partners:** None

**Number of employees:** 14

**Funds raised:** \$50 million

**Investors:** Lapam Capital, Shanghai Healthcare Capital, Wu Capital, Zhongguancun Kaiyuan Capital, TF Capital, Med-Fine Capital and LC Ventures

**CEO:** Weiwen Ying

**Patents:** None issued

said CHAMPs can also be used to degrade proteins not normally regulated by HSP90, such as mutated KRAS.

The biotech expects to reveal more about its lead program this year as it approaches the IND stage, and the round is designed to commence clinical work. Foley said plans for additional INDs could follow in the next year or so; the company is interested in treating both solid tumors and hematological malignancies.

CHAMPs are among several next-generation targeted degradation approaches that have emerged after a first wave of PROTAC companies, a handful of which have gone public.

Ranok has raised \$50 million to date, including a \$2 million seed round in June 2018 and a March 2020 series A that brought in more than \$8 million. Lapam Capital and Shanghai Healthcare Capital led the new series B alongside Wu Capital, Zhongguancun Kaiyuan

# BIOCENTURY

Capital and prior investors. Ying said Ranok will seek to add U.S. investors in a future round.

Ying and Foley were both employees at Synta Pharmaceuticals Corp., which developed HSP90 inhibitor ganetespib. Following the 2015 termination for futility of a Phase III trial of that therapy in lung cancer, Synta was part of a reverse merger that made Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) the surviving entity.

# BIOCENTURY

## EDITORIAL & RESEARCH

**NEWSROOM:**  
news@biocentury.com

SAN CARLOS, CA:  
+1 650-595-5333

CHICAGO:  
+1 312-755-0798

WASHINGTON, DC:  
+1 202-462-9582

UNITED KINGDOM:  
+44 (0)1865-512184

**C. Simone Fishburn, Ph.D.**, Editor in Chief

**Editors Emeritus:** Susan Schaeffer (2012-2018);  
Karen Bernstein, Ph.D. (1992-2012)

**Jeff Cranmer, Selina Koch, Ph.D.**, Executive Editors

**Steve Usdin**, Senior Editor/Washington & Head:  
Policy & Regulation

**Lauren Martz**, Senior Editor & Head: Translation &  
Clinical Development

**Karen Tkach Tuzman, Ph.D.**, Senior Editor & Head:  
Discovery and Preclinical Development

**Paul Bonanos, Stephen Hansen, Virginia Li**, Associate  
Editors

**Meredith Durkin Wolfe, Winnie Pong, Ph.D.**, Associate  
Editors, Data & Analytics

**Danielle Kopke, Ph.D., Gunjan Ohri, Claire Quang**, Analysts  
& Staff Writers

**Alanna Farro, Valerie Rodriguez, Cole Travis**, Graphics,  
Podcasts & Publishing

**USE OF IMAGES:** Certain Images used in BioCentury Inc.'s Publications, Video Content, Websites, Services, Notices and/or Marketing Materials are licensed from Getty Images (US), Inc. Any such image of a person or object so displayed is being used for illustrative purposes only and any such person or object depicted, if any, is merely a model. For more information see "Use of Images" found under the "Legal" section on the footer of the homepage at [www.biocentury.com](http://www.biocentury.com).

BioCentury®; Because Real Intelligence is Hard to Find™; BCIQ™; The BioCentury 100™; and The Clear Route to ROI™ are trademarks of BIOCENTURY INC. All contents Copyright © 2021, BIOCENTURY INC. ALL RIGHTS RESERVED. No part of BioCentury's Publications or Website may be copied, reproduced, retransmitted, disseminated, sold, distributed, published, broadcast, circulated, commercially exploited in any form or used to create derivative works without the written consent of BioCentury. Information provided by BioCentury's Publications and Website is gathered from sources that BioCentury believes are reliable; however, BioCentury does not guarantee the accuracy, completeness, or timeliness of the information, nor does BioCentury make any warranties of any kind regarding the information. The contents of BioCentury's Publications and Website are not intended as investment, business, tax or legal advice, and BioCentury is not responsible for any investment, business, tax or legal opinions cited therein or for any decision made or action taken in reliance upon such information.

All use of BioCentury and its contents by current subscribers is governed by the BioCentury User Agreement and by all others is governed by the BioCentury Terms of Use, unless a written agreement to the contrary has been executed by BioCentury Inc.

## CORPORATE, SUBSCRIPTIONS & PRIVACY

BioCentury's mission is to provide value-added business intelligence & analysis for life science companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.

BioCentury Inc.  
BioCentury International Inc.

### MAIN OFFICES

1235 Radio Road, Ste. 100  
Redwood City, CA 94065-1217  
+1 650-595-5333; Fax: +1 650-595-5589

### CORPORATE

**Karen Bernstein, Ph.D.**, Co-Founder & Chairman

**David Flores**, Co-Founder, President & CEO

**C. Simone Fishburn, Ph.D.**, Vice President/Editor in Chief

**Adam Gordon**: Vice President/  
Product Management & Marketing

**David Smiling**: Chief Technology Officer

**Bennet Weintraub**: Vice President/  
Administration & CFO

**Eric Pierce**: Publisher

**Susan Morgan**: Senior Director/  
Administration & Human Resources

### BUSINESS DEVELOPMENT

**Joshua Berlin**, Executive Director

**Juli Balestrieri, Hongjiang Li, Ph.D.**, Business Development  
Managers

### PRODUCT MANAGEMENT & MARKETING

**Aaron Gadowski**, Director, Product Management

**Kim Gordon**, Senior Marketing Manager

**Lam Lu**, Business Systems Manager

**Josephine Ascitutto-Bunn**, Marketing Automation Manager

**Marilyn Smith**, Customer Data Manager

### SUBSCRIBER SERVICES

**Tim Tulloch**, Senior Director

**Orlando Abello, Alan John, Matt Krebs, Michelle Ortega,  
Frank Perry, Ron Rabinowitz**, Account Managers

**Robin Leathers**, Customer Success Director

**Hannibal Adofo, Larry Campbell, Kevin Lehnbeuter**,  
Customer Success Managers

### TECHNOLOGY

**Jenny Nichols**, Director, Publishing

**Victoria Chou**, Business Intelligence Group Manager

**Alicia Parker**, Business Intelligence Analyst

**Akemi Mori**, Senior Quality Assurance Engineer

**David Ghio**, Senior IT Systems Engineer

**Deepa Srigiri**, Senior Software Engineer

**Doreen Arthur**, BioPharma Informatics Analyst

**Kelly Burris**, Senior Network Engineer

**Michael Ilyin**, Senior Data and Infrastructure Architect

**Tejpal Virk**, Data Scientist

### BUSINESS SERVICES

**Accounting & Billing:** [finance@biocentury.com](mailto:finance@biocentury.com)

**Conferences:** [conferences@biocentury.com](mailto:conferences@biocentury.com)

**Data Solutions Support:** [support@biocentury.com](mailto:support@biocentury.com)

**Privacy Policy:** [privacy@biocentury.com](mailto:privacy@biocentury.com)

**Reprints/Permissions:**  
[businessservices@biocentury.com](mailto:businessservices@biocentury.com)

### PRIVACY & ADVERTISING

In accordance with its Privacy Policy, BioCentury does NOT sell its customer information or usage data to third parties. BioCentury sells advertising in its BioCentury product emails and on its website. BioCentury is pleased to acknowledge its conference and events partners and sponsors through promotional announcements, on our web site, at our events and in our product emails. BioCentury also provides advertising opportunities to partners, sponsors, and advertisers through stand-alone emails to our community.

This edition and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact [support@biocentury.com](mailto:support@biocentury.com).